Century Therapeutics Inc. (IPSC)
Drugs • Health Care
July 09, 2026 Century Therapeutics to Showcase CNTY-813 Preclinical Data at Major Scientific Congresses Century Therapeutics announces CNTY-813's preclinical data will be presented at major scientific congresses, showcasing its potential as an innovative islet replacement therapy for type 1 diabetes. This therapy promises scalability, robust functionality, and immune protection, aiming to transform diabetes treatment.
June 08, 2026 Century Therapeutics Unveils Promising CNTY-813 Data at ADA 2026 Century Therapeutics unveiled CNTY-813 at ADA 2026, showcasing preclinical data that suggests it could offer a functional cure for type 1 diabetes. With robust glucose control and a strong safety profile, this innovative therapy aims to revolutionize diabetes treatment without the need for chronic immunosuppression.
April 30, 2026 Century Therapeutics to Present CNTY-813 Preclinical Data at ADA 2026 Century Therapeutics will present preclinical data on CNTY-813, an innovative therapy for type 1 diabetes, at the ADA 2026 Scientific Sessions. The focus will be on the Allo-Evasion™ technology aimed at improving patient access and reducing the need for lifelong immunosuppression. This marks an important milestone in advancing treatment options for autoimmune diseases.
March 12, 2026 Century Therapeutics Reports Financial Progress and Strategic Advancements Century Therapeutics reported a significant reduction in net loss for 2025, alongside a surge in collaboration revenue. The company is advancing key therapies, including CNTY-813 for type 1 diabetes, with strong financial backing and strategic initiatives set for 2026.
March 12, 2026 Century Therapeutics Inc. 2025 Annual Report: A Year of Transformation and Strategic Focus Century Therapeutics Inc. had a pivotal 2025, launching new therapies for Type 1 Diabetes and cancers while managing financial challenges. Their collaborations and innovations position them for future growth in the biotech sector.
February 25, 2026 Century Therapeutics Set to Engage Investors at Key Conferences in March 2026 Century Therapeutics is set to participate in two notable investor conferences in March 2026, showcasing its advancements in cell therapies for autoimmune diseases and cancer. The company will also provide live webcasts of the presentations for broader engagement with stakeholders.
January 08, 2026 Century Therapeutics Secures $135 Million in Oversubscribed Private Placement Financing Century Therapeutics has raised $135 million through an oversubscribed private placement, aimed at advancing CNTY-813, a therapy for Type 1 diabetes. The funding will support the company's development plans and extend its cash runway until 2029, highlighting investor confidence in its innovative approach.
December 09, 2025 Century Therapeutics Strengthens Leadership with New Board Appointments Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, aiming to boost growth in innovative therapies. The company focuses on advancing treatments for autoimmune diseases and cancer through iPSC technology. Their expertise is expected to enhance Century's strategic direction and governance.
November 25, 2025 Century Therapeutics to Showcase Innovations at Piper Sandler Conference Century Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference to discuss iPSC-derived therapies. Key presentations include a panel on cell therapy advancements and a leadership fireside chat focusing on the company's strategic vision.
November 13, 2025 Century Therapeutics Reports Third Quarter 2025 Financial Results and Business Update Century Therapeutics reported significant progress in its iPSC-derived therapies for Type 1 Diabetes and B-cell diseases during Q3 2025. The company is set to advance its lead programs, CNTY-813 and CNTY-308, towards clinical evaluation, while maintaining a strong financial position to support ongoing research.
November 13, 2025 Century Therapeutics Unveils Groundbreaking Beta Islet Program for Type 1 Diabetes Century Therapeutics has launched CNTY-813, a beta islet program aimed at revolutionizing Type 1 Diabetes treatment. Utilizing Allo-Evasion™ technology, it promises durable glycemic control without immunosuppression, backed by compelling preclinical results.
November 13, 2025 Century Therapeutics Inc. Reports Q3 2025 Financial Results: Navigating Challenges Amidst Innovation Century Therapeutics Inc. reported a net loss of $34.42 million for Q3 2025 while progressing in its cell therapy pipeline. The company is navigating financial challenges and preparing for future clinical studies amid strategic operational changes.
October 14, 2025 Century Therapeutics Set to Showcase Innovations at Chardan’s 9th Annual Genetic Medicines Conference Century Therapeutics will showcase its pioneering iPSC-derived therapies at the Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025. Led by Dr. Chad Cowan, the presentation emphasizes the company's commitment to innovative and accessible treatments for autoimmune diseases and cancer.
August 14, 2025 Century Therapeutics Inc. Reports Q2 2025 Financials: Navigating Challenges Amid Strategic Shifts Century Therapeutics Inc. reports a net loss increase in Q2 2025 while navigating significant workforce cuts and strategic shifts in product development. The company is determined to advance its innovative cell therapies despite financial challenges and a need for additional funding.
May 15, 2025 Century Therapeutics Inc. Reports Strong Q1 2025 Financial Results Amid Strategic Shifts Century Therapeutics Inc. reports strong Q1 2025 financial results with a net income of $76.56 million, a significant recovery from last year’s losses. The company is focusing on promising pre-clinical programs after terminating its lead candidate for lymphoma treatment.
March 19, 2025 Century Therapeutics Inc. Releases 2024 Annual Report: A Year of Strategic Shifts and Financial Resilience Century Therapeutics Inc. released its 2024 Annual Report showcasing increased revenues, strategic product pipeline adjustments, and ongoing partnerships. Despite a net loss, the company maintains a solid financial foundation and aims to tackle significant medical challenges.
March 19, 2025 Century Therapeutics Inc. Reports Full Year 2024 Financial Results and Strategic Business Update Century Therapeutics reported its 2024 financial results, highlighting a strategic shift towards impactful therapies. The company discontinued the ELiPSE-1 trial while expanding its CALiPSO-1 trial and initiating a new investigator-led trial for CNTY-101.
March 01, 2025 SWOT Analysis of Century Therapeutics Inc. in 2025 This article presents a detailed SWOT analysis of Century Therapeutics Inc. as of 2025, focusing on its innovative iPSC-based therapies. It highlights the company's strengths and opportunities while addressing key weaknesses and threats that could affect its growth in the competitive biotechnology landscape.
November 05, 2024 Century Therapeutics Inc. Reports Q3 2024 Financial Results Century Therapeutics Inc. reported a revenue increase to $2.4 million for Q3 2024, driven by collaborations and clinical trial advancements. Despite a net loss of $31.22 million, the company is focused on innovative cell therapies and strategic growth.
August 08, 2024 Century Therapeutics Inc. Reports Q2 2024 Financial Results: A Focus on Innovation Amidst Continued Losses Century Therapeutics Inc. reported a net loss of $31.2 million for Q2 2024, despite increased revenue and strong cash reserves. The company continues to invest heavily in R&D and strategic partnerships to advance its iPSC technology platform, positioning itself for future growth in the biotechnology sector.
May 09, 2024 Century Therapeutics Inc. Reports Q1 2024 Financial Results: A Mixed Bag for Investors Century Therapeutics Inc. reported a net loss of $28M for Q1 2024, slightly improving from last year. Despite no substantial revenue, the company maintains strong liquidity and plans to raise additional funds for R&D. Investors should monitor its progress closely as it navigates financial challenges.